Peptomyc announces the beginning of a Phase 2 clinical trial of OMO-103 in advanced osteosarcoma
Peptomyc SL, a clinical-stage biotech company focused on developing new mini-protein therapeutics targeting MYC, the most dysregulated oncogene in human cancer, announced the approval of a Phase 2 trial of OMO-103, the Company’s lead candidate, in pediatric and adult patients with advanced osteosarcoma. Read more
Accure Therapeutics partner Oculis reached positive phase 2 results for lead neuroprotective therapy
Accure Therapeutics, a private translational neuroscience R&D company, today announces the positive results of ACUITY, a phase 2 trial involving a drug candidate that was out-licensed in 2022 to Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (‘Oculis’), a global biopharmaceutical company purpose-driven to save sight and improve eye care. Read more
Peptomyc announces Research IND Approval for Innovative Window of Opportunity Trial in Collaboration with OHSU Knight Cancer Institute, Portland, Oregon, USA, in PDAC patients
Peptomyc is pleased to announce the approval of a Research Investigational New Drug (IND) application for a groundbreaking Window of Opportunity trial in collaboration with Oregon Health & Science University (OHSU) Knight Cancer Institute and Brenden-Colson Center for Pancreatic Care (BCCPC). This trial will evaluate the pharmacodynamic effects of OMO-103 in patients with pancreatic ductal […]
deepull receives FDA Breakthrough Device Designation for its UllCORE Bloodstream Infection Test
deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification, announced today that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its UllCORE Bloodstream Infection (BSI) Test. Read more
INBRAIN Neuroelectronics Raises $50M Series B to Advance Graphene-Based Brain-Computer Interface Technology
INBRAIN Neuroelectronics, a brain-computer interface therapeutics (BCI-Tx) company developing graphene-based neural technologies, today announced the close of a $50 million Series B financing round. The round was led by imec.xpand with new investors EIC Fund, Fond ICO Next Tech, CDTI-Innvierte and Avançsa. Existing investors Asabys Partners, Aliath Bioventures and Vsquared also participated, bringing the total […]
Inbiomotion and SPA – Società Prodotti Antibiotici (SPA Farma) sign an exclusive agreement for MAF Test in Italy
SPA Farma, a leading pharmaceutical company of innovative healthcare products and diagnostic tools, and Inbiomotion, proprietors of MAF Test for identifying high risk early-stage breast cancer patients, have signed an exclusive agreement to start offering the MAF Test in Italy. Read more
Ultrathin Graphene Brain Implant Was Just Tested in a Person
A Spanish biotech company sees the carbon material as a way to power the brain-computer interfaces of the future. Read more
Peptomyc Expands its Patent Portfolio with a Patent Grant in Hong Kong for its Methods and Composition for the Treatment of Cancer
Peptomyc S.L., a company developing foundational mini-protein therapeutics for the treatment of cancer, announces today that the Company has been issued a patent by the Hong Kong Patent Office protecting its Methods and Composition of Matter. Read more
Todosalud Incorporates Mediktor’s AI into Its Services as Part of Its Commitment to Innovation
Synergia Inversiones and Negocios S.A.S. are adding Mediktor’s advanced AI virtual assistant, called Frank, to its todosalud digital health platform. Users will have access to a 24/7 solution to assess their symptoms and be directed to the appropriate level of care. Read more
Mediktor Acquires Sensely and Consolidates Its Position as a Leader in AI Healthcare Solutions
Mediktor, the leading digital healthcare company, has announced the acquisition of Sensely, a San Francisco-based, digital healthcare provider that pioneered an empathy-driven conversation platform to support hospital systems and insurance services with world-class member engagement. This consolidation of two world-leading artificial intelligence-driven solutions providers marks a major medical technology milestone, extending Mediktor’s global presence to […]
